About BioCryst Pharmaceuticals Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.biocryst.com/
Frequently Asked Questions
What is the 52-week range for BCRX?
The 52-week high is $11.22 and the 52-week low is $6.
What is the P/E ratio for BCRX?
The P/E ratio data is currently unavailable.
What is the dividend yield for BCRX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -328.82%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -40.90%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 13.88.
Analyst Recommendation Trends
Wall Street analyst consensus for BCRX over the last few months:
Latest BCRX News
JP Morgan Maintains Neutral on BioCryst Pharma, Raises Price Target to $13
JP Morgan analyst Jessica Fye maintains BioCryst Pharma (NASDAQ:BCRX) with a Neutral and raises the price target from $12 to $13.
Claude AI Just Bought These 2 Pharma Stocks
Note: The stock trades discussed in this article come from AI Finance Labs, an investment experiment that operates publicly viewable portfolios directed by models including Claude, ChatGPT, Grok and DeepSeek. Anthropic’s Claude AI recently sold its positions in Ardelyx Inc. (NASDAQ: ARDX) and Aris Mining Corp. (NYSE: ARIS) and replaced them with Syndax Pharmaceuticals Inc. […]
Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine
Novo Nordisk A/Sâs 2030 pipeline targets, Wegovy pill growth and Q2 sales show major upside. Click for this NVO stock update.
Is BioCryst’s (BCRX) Newest Approval Bigger Than It Looks?
Beneath the headline-driven sentiment of biotech investing lies the true engine of value creation: portfolio durability, capital efficiency, and sustainable revenue compounding. Founded on the promise of structure-based drug design, BioCryst Pharmaceuticals (NASDAQ:BCRX) has evolved from a speculative research shop into a commercial-stage rare disease specialist. The company’s core operational drivers now center on maximizing […]
Biopharma Stock With Layers of Technical Support in Place
BCRX is flashing a historically bullish signal
BioCryst Eyes $1B Rare-Disease Future Through External Innovation
BioCryst Pharmaceuticals (NASDAQ:BCRX) is shifting its strategy toward external innovation as it seeks to expand beyond its ORLADEYO hereditary angioedema, or HAE, franchise, newly appointed Chief Executive Officer Charlie Gayer said at a Morgan Stanley event. Gayer, who became CEO on Jan. 1, said
4 Biotech Stocks to Watch as Potential Takeover Targets
Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.
BioCryst (BCRX) Turns its First Profit and Now Wants to Go Shopping for Rare Disease Drugs
On August 28, 2026, CNBC reported that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), now consistently profitable on the strength of its hereditary angioedema drug “Orladeyo,” is looking to acquire more rare disease treatments, according to CEO Charlie Gayer. Gayer, who took the role in January, said the company expects to keep growing profits every year and does […]
PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
Pharvaris gains as strong phase III data show deucrictibant XR reduces HAE attacks 83%, supporting plans for regulatory submissions in 2027.
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BioCryst Pharmaceuticals, Inc. (BCRX) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 9:15 AM EDTCompany ParticipantsCharles...
BioCryst Pharmaceuticals (BCRX) Could Be 62% Undervalued On Its ORLADEYO Growth Story
BioCryst Pharmaceuticals (BCRX) has drawn fresh attention after recent trading left the share price at US$8.12, with the stock down over the past week and month but modestly higher year to date. Recent trading tells a mixed story for BioCryst Pharmaceuticals, with the share price falling 18.47% over the past week and 16.63% over the past month, yet still showing an 8.27% year to date share price return and a 5.45% one year total shareholder return. This suggests that short term momentum is...
BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity
BioCryst Pharmaceuticals, Inc. stock update: Orladeyo Q2 revenue rose 6.7%, debt fell, and navenibart adds HAE upside. Click for more on BCRX.
Sector Update: Healthcare Stocks Softer in Afternoon Trading
Healthcare stocks declined Thursday afternoon, with the NYSE Healthcare Index shedding 0.2% and the
BCRX Stock Heads For Fifth Straight Day In The Red – RBC Capital Says BioCryst Faces A ‘Challenging Near-Term Outlook’
RBC Capital said it expects revenue tailwinds for BioCryst’s Orladeyo drug after Pharvaris posted strong Phase 3 data for HAE therapy.
BioCryst Pharmaceuticals Faces Competitive Pressure in Hereditary Angioedema Treatment, RBC Says
BioCryst Pharmaceuticals' (BCRX) Ordaleyo faces competitive pressure in the hereditary angioedema tr
RBC Capital Downgrades BioCryst Pharma to Sector Perform, Lowers Price Target to $11
RBC Capital analyst Brian Abrahams downgrades BioCryst Pharma (NASDAQ:BCRX) from Outperform to Sector Perform and lowers the price target from $13 to $11.
BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease
Pharvaris said on Tuesday its once-daily experimental pill cut monthly swelling attacks by 83% versus a dummy treatment in a late-stage study of hereditary angioedema patients.
CareMed Has Been Selected as a National Pharmacy Partner by BioCryst and Adds Orladeyo® (berotralstat) to Growing Rare Disease Portfolio
NEW HYDE PARK, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CareMed, an independent specialty pharmacy, has been selected as a pharmacy partner by BioCryst Pharmaceuticals for Orladeyo® (berotralstat), a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years and older.1 “The addition of Orladeyo reinforces our long-term commitment to supporting rare and complex disease, highlights the strength of our specialty
Needham Reiterates Buy on BioCryst Pharma, Maintains $16 Price Target
Needham analyst Serge Belanger reiterates BioCryst Pharma (NASDAQ:BCRX) with a Buy and maintains $16 price target.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-31 | McKee Amy E | +644 | $9.7 | $6,247 |
| 2026-08-31 | Milne Jill C. | +1,288 | $9.7 | $12,494 |
| 2026-08-31 | Frank Steven | +1,288 | $9.7 | $12,494 |
| 2026-08-31 | Stonehouse Jon P | +644 | $9.7 | $6,247 |
| 2026-08-31 | MILANO VINCENT | +1,159 | $9.7 | $11,242 |
| 2026-06-11 | McKee Amy E | +33,540 | - | - |
| 2026-06-11 | McKee Amy E | +15,294 | - | - |
| 2026-06-11 | HEGGIE THERESA | +33,540 | - | - |
| 2026-06-11 | HEGGIE THERESA | +15,294 | - | - |
| 2026-06-11 | SANDERS MACHELLE | +33,540 | - | - |
| 2026-06-11 | SANDERS MACHELLE | +15,294 | - | - |
| 2026-06-11 | Milne Jill C. | +33,540 | - | - |
| 2026-06-11 | Milne Jill C. | +15,294 | - | - |
| 2026-06-11 | Frank Steven | +33,540 | - | - |
| 2026-06-11 | Frank Steven | +15,294 | - | - |
| 2026-06-11 | Galson Steven K | +33,540 | - | - |
| 2026-06-11 | Galson Steven K | +15,294 | - | - |
| 2026-06-11 | Stonehouse Jon P | +33,540 | - | - |
| 2026-06-11 | Stonehouse Jon P | +15,294 | - | - |
| 2026-06-11 | MILANO VINCENT | +33,540 | - | - |
| 2026-06-11 | MILANO VINCENT | +15,294 | - | - |
| 2026-06-11 | LEVIN ALAN G | +33,540 | - | - |
| 2026-06-11 | LEVIN ALAN G | +15,294 | - | - |
| 2026-05-29 | McKee Amy E | +631 | $8.91 | $5,622 |
| 2026-05-29 | Milne Jill C. | +1,262 | $8.91 | $11,244 |
| 2026-05-29 | Frank Steven | +1,262 | $8.91 | $11,244 |
| 2026-05-29 | Stonehouse Jon P | +631 | $8.91 | $5,622 |
| 2026-05-29 | MILANO VINCENT | +1,122 | $8.91 | $9,997 |
| 2026-05-18 | McKee Amy E | -11,180 | $8.97 | $100,285 |
| 2026-05-13 | Barnes Alane P | -62,500 | - | - |
| 2026-05-13 | Barnes Alane P | -62,500 | $9.54 | $596,250 |
| 2026-05-13 | Barnes Alane P | +62,500 | $5.04 | $315,000 |
| 2026-04-06 | Menon Sandeep | +441,350 | - | - |
| 2026-04-06 | Menon Sandeep | +205,150 | - | - |
| 2026-03-20 | HEGGIE THERESA | -49,933 | - | - |
| 2026-03-20 | HEGGIE THERESA | -49,933 | $10.11 | $504,823 |
| 2026-03-20 | HEGGIE THERESA | +49,933 | $6.3 | $314,578 |
| 2026-03-16 | Barnes Alane P | -150,000 | - | - |
| 2026-03-16 | Barnes Alane P | -150,000 | $9.15 | $1,372,500 |
| 2026-03-16 | Barnes Alane P | +150,000 | $5.51 | $826,500 |
| 2026-03-02 | Stonehouse Jon P | -305,995 | - | - |
| 2026-03-02 | Stonehouse Jon P | -305,995 | $8.64 | $2,643,797 |
| 2026-03-02 | Stonehouse Jon P | +305,995 | $3.22 | $985,304 |
| 2026-02-27 | Milne Jill C. | +528 | $8.75 | $4,620 |
| 2026-02-27 | Frank Steven | +1,285 | $8.75 | $11,244 |
| 2026-02-27 | Stonehouse Jon P | +421 | $8.75 | $3,684 |
| 2026-02-27 | MILANO VINCENT | +848 | $8.75 | $7,420 |
| 2026-02-27 | McKee Amy E | +642 | $8.75 | $5,618 |
| 2026-01-23 | Milne Jill C. | +26,684 | - | - |
| 2026-01-23 | Milne Jill C. | +12,272 | - | - |
| 2026-01-23 | Milne Jill C. | +2,582 | - | - |
| 2025-12-22 | Gayer Charles K | -50,000 | - | - |
| 2025-12-22 | Gayer Charles K | -10,091 | - | - |
| 2025-12-22 | Gayer Charles K | -14,142 | - | - |
| 2025-12-22 | Gayer Charles K | +50,000 | $5.51 | $275,500 |
| 2025-12-22 | Gayer Charles K | +10,091 | $5.04 | $50,859 |
| 2025-12-22 | Gayer Charles K | +14,142 | $3.22 | $45,537 |
| 2025-12-22 | Barnes Alane P | -21,773 | $7.65 | $166,563 |
| 2025-12-19 | Gayer Charles K | -11,477 | $7.41 | $85,045 |
| 2025-12-19 | Barnes Alane P | -16,902 | $7.41 | $125,244 |
| 2025-12-19 | Stonehouse Jon P | -61,793 | $7.41 | $457,886 |
| 2025-12-18 | Stonehouse Jon P | +10,000 | - | - |
| 2025-12-18 | Stonehouse Jon P | +10,000 | - | - |
| 2025-12-18 | Stonehouse Jon P | -20,000 | - | - |
| 2025-12-17 | Ghias Babar | +355,050 | - | - |
| 2025-12-17 | Ghias Babar | +121,700 | - | - |
| 2025-12-17 | Gayer Charles K | +986,950 | - | - |
| 2025-12-17 | Gayer Charles K | +471,000 | - | - |
| 2025-12-17 | Barnes Alane P | +255,050 | - | - |
| 2025-12-17 | Barnes Alane P | +121,700 | - | - |
| 2025-12-15 | Barnes Alane P | -21,210 | $7.65 | $162,257 |
| 2025-12-12 | Gayer Charles K | -8,181 | $7.57 | $61,930 |
| 2025-12-12 | Barnes Alane P | -8,540 | $7.57 | $64,648 |
| 2025-12-12 | Stonehouse Jon P | -27,368 | $7.57 | $207,176 |
| 2025-12-03 | Barnes Alane P | -19,770 | $7.65 | $151,241 |
| 2025-12-02 | Barnes Alane P | -50,906 | $7.2136 | $367,216 |
| 2025-12-01 | Barnes Alane P | -91,004 | - | - |
| 2025-12-01 | Barnes Alane P | -91,004 | $7.1042 | $646,511 |
| 2025-12-01 | Barnes Alane P | +91,004 | $3.22 | $293,033 |
| 2025-11-28 | McKee Amy E | +783 | $7.18 | $5,622 |
| 2025-11-28 | Frank Steven | +1,566 | $7.18 | $11,244 |
| 2025-11-28 | MILANO VINCENT | +783 | $7.18 | $5,622 |
| 2025-11-13 | SANDERS MACHELLE | -9,600 | $7.14 | $68,544 |